

Figure S1




Figure S1. Example of normalization of raw ELISA data using the MTS viability OD value. (A) Calculation used to determine normalized analyte concentration. These normalized analyte

concentration values are the data presented in the manuscript. (B) Absolute OD value from MTS assay shown in Figure 6E used to normalize data in Figure 6F. (C) Differences in raw ELISA data vs. normalized ELISA data from Figure 6F. When data is not normalized, no differences can be seen between [IL-6] in the LPS vs. LPS+Narc group.

Figure S2




Figure S2. Full western blots with split and merged (680-Red and 800-Green) channels.

Figure S3






Figure S3. Secondary only controls for IMG cell staining.

Figure S4


A.




B.




C.




D.




E.




F.




G.



H.



I.



J.




Figure S4. MTS assays used throughout studies for normalization of cytokine concentrations.

(A) IMG cells and PMg (B) LPS dose response. (C) Toxicity of Y27632 with 10ng/mL LPS challenge establishing top dose (100 μ M) used in subsequent studies. (D) IMG and (E) PMg Y27632 dose-response against LPS (10 ng/mL) challenge. (F) Toxicity of RKI1447 with 10ng/mL LPS challenge establishing top dose (30 μ M) used in subsequent studies. (G) IMG and (H) PMg RKI1447 dose-response against LPS (10 ng/mL) challenge. (I) LPS (2 ng/mL) and Nogo-P4 (60 μ M). (J) siRNA treatments vs LPS (2 ng/mL) challenge (cytokine assessment experiment). One-way ANOVA with Dunnett's (A-H AND J, compared to vehicle or LPS alone) or Tukey's (I) multiple comparisons was used for statistical analysis with error bars representing mean \pm SEM; **= $p < .01$, ***= $p < .001$, and ****= $p < .0001$.